Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Formation And Characterization Of Cyclosporine-loaded Nanoparticles.

M. Guzmán, J. Molpeceres, F. García, M. R. Aberturas, M. Rodriguez
Published 1993 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The commercially available formulations of cyclosporine (cyclosporin A, CyA) are associated with acute hemodynamic changes that result in high nephrotoxicity. Among colloidal vectors, nanoparticles (NPs) are receiving much attention as potential drug carriers that would avoid the therapeutic risks of conventional formulations. Two different mechanisms for obtaining polymeric NPs loaded with CyA were studied with regard to their preparation and physicochemical characterization. Isobutyl-2-cyanoacrylate monomer (IBCA) was polymerized, whereas poly-E-caprolactone (PCL, a preformed polymer) was precipitated; both reactions took place in an aqueous medium containing Pluronic F-68 (polyoxypropylene polyoxyethylene block copolymer) as a surface active agent. The encapsulation efficiencies were 78.49 +/- 5.87 and 84.85 +/- 5.02%, respectively, and they remained stable over a wide range of drug concentrations. The polymeric NP had average sizes of 81 +/- 25 and 95 +/- 25 nm for poly-IBCA and PCL, respectively, as confirmed by photon correlation spectroscopy. Poly-IBCA NPs were built from oligomers with molecular weights of 157 to 2644 that joined to form a polymeric nanomatrix. In vitro activity of the drug and the carrier was tested by inhibition of lymphocyte proliferation induced by Concanavalin A. Drug-loaded PCL NPs and free CyA inhibited lymphocyte proliferation by 91.40 and 86.19%, respectively. However, drug-free NPs also exhibited statistically significant (p < 0.05) immunosuppressive activity.
This paper references
10.1016/0009-3084(88)90128-4
Interaction of cyclosporin A with 1,2-dimyristoyl-sn-glycero-3-phosphocholine unilamellar vesicles studied by electron spin resonance
L. Stuhne-Sekalec (1988)
10.1248/CPB.37.471
Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics.
K. Takada (1989)
10.1097/00007890-198605000-00024
Encapsulation of cyclosporine by phosphatidylinositol-cholesterol liposomes.
L. Stuhne-Sekalec (1986)
10.1016/0378-5173(89)90300-1
Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine
K. Vadiei (1989)
10.1002/JPS.2600681215
Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum.
P. Couvreur (1979)
10.7326/0003-4819-101-5-667
Cyclosporine: a new immunosuppressive agent for organ transplantation.
D. Cohen (1984)
10.1016/0378-5173(86)90131-6
Evaluation of carrier capacity and release characteristics for poly( butyl 2-cyanoacrylate) nanoparticles
L. Illum (1986)
10.1002/JPS.2600790307
Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid.
S. Venkataram (1990)
10.1016/0169-409X(91)90048-H
Peroral administration of nanoparticles
J. Kreuter (1991)
10.3109/03639048809151937
Controlled Release of Cyclosporine from Microspheres
M. D'souza (1988)
10.1016/0142-9612(86)90091-8
Phagocytosis of latex particles by leucocytes. I. Dependence of phagocytosis on the size and surface potential of particles.
H. Kawaguchi (1986)
Cyclosporine analysis by high-performance liquid chromatography: precision, accuracy, and minimum detectable quantity.
Bowers Ld (1990)
10.1016/0378-5173(86)90236-X
Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules
N. A. K. Fallouh (1986)
10.1111/j.2042-7158.1990.tb07033.x
Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
P. Jani (1990)
10.1056/NEJM198409133111109
Cyclosporine-Induced Nephrotoxicity
T. Strom (1984)
10.3109/02652048909098016
Selective transfer of cyclosporin to thoracic lymphatic systems by the application of lipid microspheres.
A. Yanagawa (1989)
10.1210/ENDO-129-6-2915
Cytokine regulation of the mucosal immune system: in vivo stimulation by interferon-gamma of secretory component and immunoglobulin A in uterine secretions and proliferation of lymphocytes from spleen.
R. Prabhala (1991)
10.1016/0378-5173(89)90281-0
Nanocapsule formation by interfacial polymer deposition following solvent displacement
H. Fessi (1989)



This paper is referenced by
10.1557/MRS2007.164
Nanotechnology and related safety issues for delivery of active ingredients in cosmetics
P. Somasundaran (2007)
10.1016/0142-9612(96)81411-6
Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs.
M. Fresta (1996)
10.2174/157341310791658937
Cyclosporin A Loaded PLGA Nanoparticle: Preparation, Optimization, In-Vitro Characterization and Stability Studies
S. Jain (2010)
10.1016/J.JCONREL.2004.01.017
Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process.
J. Jaiswal (2004)
10.1016/J.DRUDIS.2006.07.015
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
J. L. Italia (2006)
10.1016/S0939-6411(00)00125-9
Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs.
A. Saez (2000)
10.3109/02652049709006828
Stability of cyclosporine-loaded poly-X-caprolactone nanoparticles
J. Molpeceres (1997)
10.1016/J.IJPHARM.2005.01.025
In vitro and in vivo studies of cyclosporin A-loaded microspheres based on copolymers of lactide and epsilon-caprolactone: comparison with conventional PLGA microspheres.
Y. Li (2005)
10.1016/J.IJPHARM.2007.08.050
Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability.
J. Woo (2007)
10.22028/D291-22973
Exploring the follicular route for transcutaneous vaccination using nanoparticles
A. Mittal (2014)
10.1080/02652040400008507
Development and characterization of different low methoxy pectin microcapsules by an emulsion–interface reaction technique
Z. Muhiddinov (2004)
10.2147/IJN.S12125
Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method
Z. Urbán-Morlán (2010)
10.1016/S1773-2247(04)50080-1
Novel colloidal delivery systems for dermal application
M. Schubert (2004)
10.3109/03639049809108571
Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers.
D. Quintanar-Guerrero (1998)
10.1016/S0378-5173(97)00138-5
Ciproflexacin-loaded polyisobutylcyanoacrylate nanoparticles: Preparation and characterization
F. Fawaz (1997)
10.1016/0378-5173(96)04618-2
Optimized preparation of poly d,l (lactic-glycolic) microspheres and nanoparticles for oral administration
M. Chacón (1996)
10.1016/J.IJPHARM.2004.01.044
Poly-ϵ-caprolactone microspheres and nanospheres: an overview
V. Sinha (2004)
10.1201/9780203913338.CH18
Biodegradable Nanoparticles as Drug Delivery Systems for Parenteral Administration
Michael Chorny (2003)
10.1016/S0378-5173(98)00198-7
Age and sex dependent pharmacokinetics of cyclosporine in the rat after a single intravenous dose
J. Molpeceres (1998)
10.1016/0378-5173(95)04294-6
Exothermic-endothermic heat of solution shift of cyclosporin a related to poloxamer 188 behavior in aqueous solutions
J. Molpeceres (1996)
10.1016/S0928-0987(00)00198-6
Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats.
M. C. Varela (2001)
10.1021/JS950164R
Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement.
J. Molpeceres (1996)
10.1016/J.COLSURFA.2018.07.005
Polyelectrolyte-coated nanocapsules containing cyclosporine A protect neuronal-like cells against oxidative stress-induced cell damage
M. Piotrowski (2018)
10.1016/J.IJPHARM.2004.09.019
Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles.
N. Ubrich (2005)
10.1080/026520400417658
Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization.
J. Molpeceres (2000)
10.1016/S0928-0987(98)00066-9
Stability and freeze-drying of cyclosporine loaded poly(D,L lactide-glycolide) carriers.
M. Chacón (1999)
10.1016/S0378-5173(99)00177-5
A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy.
J. Molpeceres (1999)
10.1016/J.EJPB.2004.03.028
Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration.
C. Müller-Goymann (2004)
Composition et procede de preparation de microparticules de substances insolubles dans l'eau
S. Khan (1999)
10.1166/JBN.2007.016
Nanoparticular Drug Delivery System of Cytarabine Hydrochloride (CTH) for Improved Treatment of Lymphoma
K. Ruckmani (2007)
10.3109/10611869808997871
Drug delivery systems for cyclosporine: achievements and complications.
B. A. Klyashchitsky (1998)
10.15520/JMBAS.2014.VOL1.ISS6.19.PP
Nanoparticulate Drug Delivery System of Geriforte
Maruthappan (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar